Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices Andrew T. Kuykendall Review Article Open access 21 March 2023 Pages: 985 - 993
Stem cell mobilization in multiple myeloma: challenges, strategies, and current developments Xiaolei WeiYongqiang Wei Review Article Open access 22 March 2023 Pages: 995 - 1009
Superiority of polatuzumab vedotin over other novel agents in previously untreated ABC-type diffuse large B-cell lymphoma: a network meta-analysis of 20 RCTs Zhixin ShengDianfang LiLida Wang Review Article 22 March 2023 Pages: 1011 - 1017
Estimated glomerular filtration rate in Brazilian adults with sickle cell disease: results from the REDS-III multicenter cohort study André Rolim BelisárioAna Cristina Simões e Silvafor the Recipient Epidemiology and Donor Evaluation Study (REDS-III) International Component Brazil Original Article 08 March 2023 Pages: 1019 - 1027
Targeted next-generation sequencing identifies eighteen novel mutations expanding the molecular and clinical spectrum of PKLR gene disorders in the Indian population Rashmi DongerdiyeMeghana BokdePrabhakar Kedar Original Article 09 March 2023 Pages: 1029 - 1036
The occurrence of thrombosis during intensive chemotherapy treatment for acute myeloid leukemia patients does not impact on long-term survival Tamer HellouOmri CohenJonathan Canaani Original Article 11 March 2023 Pages: 1037 - 1043
Diagnostic yield, indications, and outcomes of cranial imaging in AML patients admitted for intensive induction or consolidation chemotherapy: a single-center experience Sebastian E. KoschadeJan A. StratmannOlivier Ballo Original Article Open access 22 March 2023 Pages: 1045 - 1052
Epidemiology and early mortality patterns of acute promyelocytic leukemia in the United States Aditi SharmaJay YangVijendra Singh Original Article 14 March 2023 Pages: 1053 - 1062
Loss of IRF8 inhibits the growth of acute myeloid leukemia cells Haihui ZhuangFenglin LiYing Lu Original Article 23 March 2023 Pages: 1063 - 1072
Lycorine induces apoptosis of acute myeloid leukemia cells and inhibits triglyceride production via binding and targeting FABP5 Xinming LiangWenli FuQifang Zhang Original Article 21 March 2023 Pages: 1073 - 1086
PH negative acute lymphoblastic leukemia in adolescents and young adults treated according a MRD adapted BFM ALL IC 2009 protocol: Argentine real-world data on 171 patients Luciana C FerrariMaría M RivasOn behalf of the Grupo Argentino de Leucemias Agudas (GALA) and Grupo Argentino de Tratamiento de Leucemias Agudas (GATLA) Original Article 09 March 2023 Pages: 1087 - 1097
Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia treated with acute myeloid leukemia–like or acute lymphoblastic leukemia–like chemotherapy and impact of allogeneic stem cell transplantation: a Campus ALL study Davide LazzarottoIlaria TanasiRobin Foà Original Article 24 March 2023 Pages: 1099 - 1109
Long term outcomes in older patients with primary central nervous system lymphoma: an analysis of the Texas Cancer Registry Ethan A. BurnsCesar Gentille SanchezSai Ravi Kiran Pingali Original Article 16 March 2023 Pages: 1111 - 1120
Clinical and histopathology characteristics of Castleman disease: a multicenter study of 51 Brazilian patients Julia Mota LeiteTomás Zecchini BarreseCarlos Sérgio Chiattone Original Article 10 February 2023 Pages: 1121 - 1129
Pediatric chemotherapy versus allo-HSCT for adolescent and adult Philadelphia chromosome-negative ALL in first complete remission: a meta-analysis Zengkai PanLuxiang WangXiaoxia Hu Original Article 22 March 2023 Pages: 1131 - 1140
Prognostic value of metabolic tumor volume of extranodal involvement in diffuse large B cell lymphoma Kana OiwaKei FujitaTakahiro Yamauchi Original Article Open access 23 March 2023 Pages: 1141 - 1148
Real-world data from yttrium-90 ibritumomab tiuxetan treatment of relapsed or refractory indolent B-cell non-Hodgkin's lymphoma: J3Zi Study Ilseung ChoiMasaya OkadaTomoki Ito Original Article 30 March 2023 Pages: 1149 - 1158
Systemic relapses of primary CNS lymphomas (PCNSL): a LOC network study J. DufourS. ChoquetC. Houillier Original Article 29 March 2023 Pages: 1159 - 1169
Real world outcomes of lenalidomide or bortezomib maintenance in patients with multiple myeloma not undergoing stem cell transplantation Tianhong XuYang YangPeng Liu Original Article 08 March 2023 Pages: 1171 - 1184
Clinical significance of high-dose chemotherapy with autologous stem cell transplantation in the era of novel agents in patients older than 65 years with multiple myeloma Shuku SatoShun TsunodaYotaro Tamai Original Article Open access 23 March 2023 Pages: 1185 - 1191
CMV infection is a risk factor for hemorrhagic cystitis after hematopoietic stem cell transplantation Ling ZhangBijay KhadkaJiajun Liu Original Article 08 February 2023 Pages: 1193 - 1201
Feasibility, safety, and efficacy of early prophylactic donor lymphocyte infusion after T cell-depleted allogeneic stem cell transplantation in acute leukemia patients Boris van der ZouwenE. A. S. KosterC. J. M. Halkes Original Article Open access 07 March 2023 Pages: 1203 - 1213
Allogeneic transplantation of bone marrow versus peripheral blood stem cells from HLA-identical relatives in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukemia: a propensity score analysis of a nationwide database Hidehiro ItonagaYasushi MiyazakiKen Ishiyama Original Article 15 March 2023 Pages: 1215 - 1227
Ferroptosis: a new target for iron overload-induced hemophilic arthropathy synovitis Zhiwei HanLiujie ZhengYunfeng Yao Original Article 23 March 2023 Pages: 1229 - 1237
Predictive scoring system for distinguishing Stenotrophomonas maltophilia bacteremia from Pseudomonas aeruginosa bacteremia in patients with hematological malignancies Takashi SakohMuneyoshi KimuraHideki Araoka Original Article 27 March 2023 Pages: 1239 - 1246
High TOX expression on CD8+ T cells in pure red cell aplasia Haiyue NiuLi YanHuaquan Wang Original Article 18 March 2023 Pages: 1247 - 1255
Effectiveness and management of ponatinib as second-line treatment in chronic myeloid leukemia: an analysis from the monitoring registries of the Italian medicines agency (AIFA) Massimo BrecciaPier Paolo OlimpieriPierluigi Russo Letter to the Editor 13 March 2023 Pages: 1257 - 1259
Use of roxadustat (FG-4592) in ruxolitinib-treatment-related anemia of two myelofibrosis patients Kai DingZhaoyun LiuRong Fu Letter to the Editor Open access 13 March 2023 Pages: 1261 - 1263
Remarkable response to chidamide plus rituximab in an elderly patient with recurrent, chemotherapy-refractory diffuse larger B-cell lymphoma carrying CREBBP mutation Dongdong ZhangYidi HanYouhong Dong Letter to the Editor 29 March 2023 Pages: 1265 - 1268
Safe and successful CAR T-cell therapy targeting BCMA in a multiple myeloma patient requiring hemodialysis Ralph WäschTim StrüssmannMonika Engelhardt Letter to the Editor Open access 17 March 2023 Pages: 1269 - 1270
Sustained spontaneous remission in KMT2A-MLLT3 mutated myeloid sarcoma Chris ArmstrongWing-Yan AuNina Orfali Letter to the Editor 17 March 2023 Pages: 1271 - 1274
Venetoclax and blinatumomab based chemotherapy-free treatment in a patient with Philadelphia chromosome-negative acute lymphoblastic leukemia Jie ChangYao-jia ShenHong-Hu Zhu Letter to the Editor 09 March 2023 Pages: 1275 - 1277
JAK2 V617F-mutated polycythemia vera developing in a patient with a 20-year-long chronic myeloid leukemia at the time of first molecular response Luca TosoniDora FabbroMario Tiribelli Letter to the Editor 22 March 2023 Pages: 1279 - 1280
Double-hit follicular lymphoma diagnosed due to central nervous system symptoms Chika Kawajiri-ManakoTatsuzo MishinaMasahiro Takeuchi Letter to the Editor 27 March 2023 Pages: 1281 - 1282
Real-world treatment patterns of venetoclax and azacytidine therapy in Japanese patients with acute myeloid leukemia Yoshito GandoTakeo Yasu Letter to the Editor 29 March 2023 Pages: 1283 - 1285